“I am delighted we are partnering with Zimmer Biomet to deliver our new genex Bone Graft Substitute product to the U.S. market,” shared Michael Harris, Chief Executive Officer of Biocomposites, in a news release. “genex is already used and valued by surgeons in over 30 countries, including the US, undertaking 15,000 cases each year. The upgraded offering which we are providing to Zimmer Biomet will further benefit many more physicians and patients across the U.S.”
Added Brian Hatcher, President of Zimmer Biomet’s CMFT, Foot & Ankle and Trauma: “We are excited to partner with Biocomposites to bring the new genex Bone Graft Substitute kits to surgeons as we continue to advance our mission to alleviate pain and improve the quality of life for people around the world.”
The company explained that genex Bone Graft Substitute consists of a 50:50 biphasic composition of calcium sulfate and β-tricalcium phosphate developed to balance osteoconductive scaffold strength and persistence in the body to enable the optimal remodelling of bone architecture.1 It also has a negatively charged surface chemistry that has demonstrated a favourable osteogenic bone growth response up to five times normal (positively charged) levels, InVitro.2 In addition, the proprietary recrystallization and purification production methods give genex its distinct properties and removes slow and non-absorbing compounds, such as hydroxyapatite, to ensure that it is completely absorbed and remodelled within 12 months.
